Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1037967

registered interest
date	08/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	CJD
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve diagnosis rates of sporadic Creutzfeldt-Jakob disease.
tabling member constituency	Witham
tabling member printed	Priti Patel
uin	206318
answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206320 206323 206326 206327 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
tabling member	4066 label Biography information for Priti Patel

1037969

registered interest
date	08/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	CJD
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the symptoms of sporadic Creutzfeldt-Jakob disease are identified at the earliest opportunity.
tabling member constituency	Witham
tabling member printed	Priti Patel
uin	206320
answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206318 206323 206326 206327 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
tabling member	4066 label Biography information for Priti Patel

1037974

registered interest
date	08/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	CJD
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people were diagnosed with sporadic Creutzfeldt-Jakob Disease in (a) Witham constituency, (b) the East of England and (c) England and Wales in the most recent five years for which data is available.
tabling member constituency	Witham
tabling member printed	Priti Patel
uin	206323
answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206318 206320 206326 206327 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
tabling member	4066 label Biography information for Priti Patel

1037977

registered interest
date	08/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	CJD
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken to raise awareness among medical professionals of the symptoms of (a) sporadic, (b) variant, (c) genetic and (d) Iatrogenic Creutzfeldt-Jakob Disease.
tabling member constituency	Witham
tabling member printed	Priti Patel
uin	206326
answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206318 206320 206323 206327 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
tabling member	4066 label Biography information for Priti Patel

1037985

registered interest
date	08/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	CJD
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the average waiting time has been for a diagnosis of sporadic Creutzfeldt-Jakob Disease (CJD) in the last five years for which data is available.
tabling member constituency	Witham
tabling member printed	Priti Patel
uin	206327
answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206318 206320 206323 206326 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
tabling member	4066 label Biography information for Priti Patel

1037808

registered interest
date	08/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Skin Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that strategies to (a) tackle and (b) prevent skin cancers are based on the most up to date research.
tabling member constituency	Weaver Vale
tabling member printed	Mike Amesbury
uin	206461
answer	answer is ministerial correction date of answer 11/01/2019 answer text <p>The NHS Long Term Plan sets out how the National Health Service plans to improve outcomes against all cancers. The Long Term Plan was developed together with stakeholders across the health and care sector, and is based on the latest evidence.</p><p> </p><p>Public Health England (PHE) is carrying out research to investigate the contribution of ultraviolet light (UV) to skin cancer in a comprehensive way, which aims to minimise the detrimental effects of UV while maximising the potential benefits of UV in vitamin D production and potentially in mitigating high blood pressure. Through public events, PHE informs the public of the risk and potential benefits of sunshine and practical measures to take to prevent skin cancer.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/01/2019 13:08:48 answering member 4067 label Biography information for Steve Brine
tabling member	4667 label Biography information for Mike Amesbury

1037922

registered interest
date	08/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dentistry: Fines
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 September 2018 to Question 167266, how many FP17 forms have not been accepted by the NHS Business Services Authority due to concerns about the address provided for the patient.
tabling member constituency	Walthamstow
tabling member printed	Stella Creasy
uin	206351
answer	answer is ministerial correction date of answer 11/01/2019 answer text <p>This information is not held.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/01/2019 13:09:18 answering member 4067 label Biography information for Steve Brine
tabling member	4088 label Biography information for Stella Creasy

1037778

registered interest
date	08/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Air Pollution
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 October 2018 to Question 174612 on Air Pollution, what plans his Department has to further study the effects of PM0.1 and PM1 particles on human health.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	206215
answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Recent assessments have been undertaken of the health effects of long-term exposure to the air pollution mixture in the United Kingdom, but no separate assessments of the impact of the PM1 and PM0.1 components (particulate matter with an aerodynamic diameter smaller than 1 or 0.1 microns, respectively) of particulate air pollution have been produced.</p><p> </p><p>The reviews by the Health Effects Institute and the World Health Organization about the effects of different components of air pollution, including ultrafine particles (PM0.1), concluded that there is currently limited evidence on the effects on health of ultrafine particles. These reviews are available at the following link:</p><p> </p><p><a href="https://www.healtheffects.org/publication/understanding-health-effects-ambient-ultrafine-particles" target="_blank">https://www.healtheffects.org/publication/understanding-health-effects-ambient-ultrafine-particles</a></p><p> </p><p><a href="http://www.euro.who.int/__data/assets/pdf_file/0004/193108/REVIHAAP-Final-technical-report-final-version.pdf?ua=1" target="_blank">http://www.euro.who.int/__data/assets/pdf_file/0004/193108/REVIHAAP-Final-technical-report-final-version.pdf?ua=1</a></p><p> </p><p>Currently, Public Health England has no plans to engage in work on the effects of PM1 and PM0.1 particles on human health over the coming year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/01/2019 12:30:56 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

1037779

registered interest
date	08/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Public Health: Fuel Poverty
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the effects of fuel poverty on public health.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	206216
answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>The causes of excess winter death and illness are complex and interlinked, and include circulating diseases such as influenza, cold temperatures and wider determinants of health, such as poor housing and fuel poverty. It is difficult to attribute the relative impacts of each of these factors as the contribution varies year on year.</p><p> </p><p>Living in a cold home and being in fuel poverty represent a significant risk to health, wellbeing and inequalities. The joint Public Health England and University College London Institute of Health Equity report ‘Local action on health inequalities: Fuel poverty and cold home-related health problems’ reported that an estimated 21.5% of annual excess winter deaths are attributable to the coldest quarter of housing. The report is available to view at the following link:</p><p> </p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/355790/Briefing7_Fuel_poverty_health_inequalities.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/355790/Briefing7_Fuel_poverty_health_inequalities.pdf</a></p><p> </p><p>The Public Health Outcomes Framework (PHOF) includes an Excess Winter Deaths Index and a Fuel Poverty indicator, available to view at the following link:</p><p> </p><p><a href="https://fingertips.phe.org.uk/search/fuel%20poverty#page/3/gid/1/pat/6/par/E12000007/ati/102/are/E09000022/iid/90356/age/1/sex/4" target="_blank">https://fingertips.phe.org.uk/search/fuel%20poverty#page/3/gid/1/pat/6/par/E12000007/ati/102/are/E09000022/iid/90356/age/1/sex/4</a></p><p> </p><p>Local government use PHOF to assess the scale of the problem locally and are supported to take action through both the Cold Weather Plan for England and the National Institute for Health and Care Excellence Guidelines.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/01/2019 12:28:53 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

1037780

registered interest
date	08/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Housing: Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect of home energy efficiency interventions on human health.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	206217
answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>The Department for Business, Energy and Industrial Strategy (BEIS) is leading a project looking at the health impacts of living in cold homes.</p><p> </p><p>BEIS is working in collaboration with the Department for Work and Pensions, Public Health England and NHS Digital to understand and quantify the cost to the health service arising from households that underheat their homes requiring more hospital care, compared to similar households who heat their homes adequately. The study will also consider the impact of households who subsequently make energy efficiency improvements and whether this leads to a reduction in hospital care required.</p><p> </p><p>The study is set to conclude later in the year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/01/2019 12:27:12 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew